Kiniksa climbs after Q1 revenue beat

Kiniksa Pharmaceuticals International

23/04/2024 15:09

** Shares of therapy developer Kiniksa Pharmaceuticals
 KNSA.O  rise ~2.2% to $17.48
    ** Co's quarterly revenue of $79.90 mln beats analysts'
average expectation of $78.50 - LSEG data
    ** Co raises annual net product revenue forecast of Arcalyst
to range between $370 mln and $390 mln, compared to prior
expectation of $360 mln to $380 mln
    ** Arcalyst is used to treat recurrent pericarditis, a
condition in which the sac-like covering around the heart
becomes inflamed 
    ** Including session's move, stock down ~1.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))